This article is more than 5 years old. Information may no longer be current.

MacuSight begins phase 1 study of liquid sirolimus

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

UNION CITY, Calif. — MacuSight Inc. has initiated a phase 1 study of its proprietary liquid formulation of sirolimus for treating diabetic macular edema, the company announced.

The six-armed randomized study will involve 30 patients and is evaluating the safety of both subconjunctival and intravitreal injections of three sirolimus doses, according to a press release.

Sirolimus is an immunosuppressant drug with antiangiogenic, antiproliferative and antimigratory activity. Wyeth currently markets a sirolimus formulation under the brand name Rapamune, which is indicated for preventing organ rejection following renal grafting. MacuSight officials believe the drug's range of activity may make it useful as both a front-line and a preventative treatment for both wet AMD and diabetic macular edema, according to the release.